In detail, engineered oHSV T7011 was used to deliver dual-blood cancer antigens, the extracellular domain of CD19 and BCMA, to solid tumor surface to activate the tumor-killing by CD19 or BCMA-specific CAR T cells. This evidence concerns the gene CD19 and neoplasm.